ArticleCancer science2020
Human papillomavirus genotype contribution to cervical cancer and precancer: Implications for screening and vaccination in Japan.
Article in Cancer science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- Type-specific detection and quantification of circulating tumor HPV DNA by digital PCR in surgically resected cervical cancer.Journal of gynecologic oncology · 2026Article
- Request for Clarification on Data Presentation in Table 2, Figures 3 and 4 of Onuki et al. (Cancer Science 2020).Cancer science · 2026Article
- Psychosocial Burden of Women With Cervical Intraepithelial Neoplasia in Japan: Results of A Web-Based Survey.The journal of obstetrics and gynaecology research · 2026Observational
- Prevalence and genotype distribution of human papillomavirus in cervical cancer and precancer in Japan between 2012 and 2025: a retrospective single-center study.Frontiers in public health · 2026Article
- Cost-effectiveness analysis of 9-valent human papillomavirus vaccine combined with screening for cervical cancer in Japan.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Article
- Association Between Human Papillomavirus and Thymic Cancer: A Population-Based Cohort Study.Cancer management and research · 2025Article
- Estimation of self-funded human papillomavirus vaccine recipients from Japan's previously assumed "unvaccinated generation".Cancer science · 2024Article
- Absolute Risk and Attributable Fraction of Type-Specific Human Papillomavirus in Cervical Cancer and Precancerous Lesions-A Population-Based Study of 6286 Women in Rural Areas of China.Journal of clinical medicine · 2022Article
- Juvenile Membranous Nephropathy Developed after Human Papillomavirus (HPV) Vaccination.Vaccines · 2022Article
- Long-term effectiveness of HPV vaccination against HPV infection in young Japanese women: Real-world data.Cancer science · 2022Article
- Article
- Article
- 5-aminolevulinic acid-mediated photodynamic therapy effectively ameliorates HPV-infected cervical intraepithelial neoplasia.American journal of translational research · 2022Article
- Cervical Cancer Protection in Japan: Where Are We?Vaccines · 2021Review
- Comparison between Urine and Cervical High-Risk HPV Tests for Japanese Women with ASC-US.Diagnostics (Basel, Switzerland) · 2021Article
- A nationwide birth year-by-year analysis of effectiveness of HPV vaccine in Japan.Cancer science · 2021Article
- Current Updates on Cancer-Causing Types of Human Papillomaviruses (HPVs) in East, Southeast, and South Asia.Cancers · 2021Review
- Human papillomavirus genotype contribution to cervical cancer and precancer: Implications for screening and vaccination in Japan.Cancer science · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 20 institutions in 1 country.
Funding
Abstract
To obtain baseline data for cervical cancer prevention in Japan, we analyzed human papillomavirus (HPV) data from 5045 Japanese women aged less than 40 years and diagnosed with cervical abnormalities at 21 hospitals during 2012-2017. These included cervical intraepithelial neoplasia grade 1 (CIN1, n = 573), CIN2-3 (n = 3219), adenocarcinoma in situ (AIS, n = 123), and invasive cervical cancer (ICC, n = 1130). The Roche Linear Array was used for HPV genotyping. The HPV type-specific relative contributions (RCs) were estimated by adding multiple infections to single types in accordance with proportional weighting attributions. Based on the comparison of type-specific RCs between CIN1 and CIN2-3/AIS/ICC (CIN2+), RC ratios were calculated to estimate type-specific risks for progression to CIN2+. Human papillomavirus DNA was detected in 85.5% of CIN1, 95.7% of CIN2-3/AIS, and 91.2% of ICC. Multiple infections decreased with disease severity: 42.9% in CIN1, 40.4% in CIN2-3/AIS, and 23.7% in ICC (P < .0001). The relative risk for progression to CIN2+ was highest for HPV16 (RC ratio 3.78, 95% confidence interval [CI] 3.01-4.98), followed by HPV31 (2.51, 1.54-5.24), HPV18 (2.43, 1.59-4.32), HPV35 (1.56, 0.43-8.36), HPV33 (1.01, 0.49-3.31), HPV52 (0.99, 0.76-1.33), and HPV58 (0.97, 0.75-1.32). The relative risk of disease progression was 1.87 (95% CI, 1.71-2.05) for HPV16/18/31/33/35/45/52/58, but only 0.17 (95% CI, 0.14-0.22) for HPV39/51/56/59/66/68. Human papillomavirus 16/18/31/33/45/52/58/6/11 included in a 9-valent vaccine contributed to 89.7% (95% CI, 88.7-90.7) of CIN2-3/AIS and 93.8% (95% CI, 92.4-95.3) of ICC. In conclusion, our data support the Japanese guidelines that recommend discriminating HPV16/18/31/33/35/45/52/58 genotypes for CIN management. The 9-valent vaccine is estimated to provide over 90% protection against ICC in young Japanese women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.